- Tainted Cucumbers Now Linked to 100 Salmonella Cases in 23 States
- Check Your Pantry, Lay’s Classic Potato Chips Recalled Due to Milk Allergy Risk
- Norovirus Sickens Hundreds on Three Cruise Ships: CDC
- Not Just Blabber: What Baby’s First Vocalizations and Coos Can Tell Us
- What’s the Link Between Memory Problems and Sexism?
- Supreme Court to Decide on South Carolina’s Bid to Cut Funding for Planned Parenthood
- Antibiotics Do Not Increase Risks for Cognitive Decline, Dementia in Older Adults, New Data Says
- A New Way to Treat Sjögren’s Disease? Researchers Are Hopeful
- Some Abortion Pill Users Surprised By Pain, Study Says
- Who is At Risk For Cybercrime?
Weight-Loss Meds Like Wegovy Could Battle Alcoholism
-300x336.jpg)
Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism and opioid addiction, a new study finds.
People taking this class of drugs, called glucagon-like peptide-1 receptor agonists (GLP-1), have a 50% lower rate of drunkenness than people with addiction disorders not on the meds, researchers reported Oct. 17 in the journal Addiction.
GLP-1 patients also have a 40% lower rate of opioid overdose, results show.
GLP-1 drugs “exhibited a strong protective association with alcohol intoxication among those with alcohol use disorder,” concluded the research team led by Fares Qeadan, an associate professor of biostatistics at Loyola University in Chicago.
“Related prescriptions additionally displayed a strong protective association with opioid overdose among individuals with opioid use disorder,” the researchers added in a journal news release.
GLP-1 drugs promote weight loss by mimicking a hormone produced in response to eating. Taking the drug helps stabilize blood sugar levels, decrease feelings of hunger and slow digestion, researchers noted.
The brain region targeted by GLP-1 “overlaps with the same processes that are responsible for the development and maintenance of addictive behaviors such as chronic substance use,” the researchers said.
For this study, researchers analyzed data on more than 500,000 people with a history of opioid addiction and 817,000 with a history of alcoholism. The data, drawn from 136 U.S. health systems, spanned January 2014 to September 2022.
Researchers tracked these folks’ use of GLP-1 drugs, as well as any bouts of intoxication or overdose they experienced.
“This study may introduce a promising new treatment for substance use disorders,” researchers said.
More information
The Cleveland Clinic has more on GLP-1 drugs.
SOURCE: Society for the Study of Addiction, news release, Oct. 17, 2024
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.
Related
-
Some Abortion Pill Users Surprised By Pain, Study SaysAbortion pills are safe and effective, but some pain...
- December 20, 2024
-
FDA: Veozah, First Hormone-Free Hot Flash Drug, Issued Black Box WarningThe U.S. Food and Drug Administration (FDA) has issued...
- December 18, 2024
-
Non-heterosexual Women Report Better Sexual Functioning During MidlifeTUESDAY, Dec. 17, 2024 A woman’s sex drive often...
- December 18, 2024
-
Task Force Supports Women Over 30 Collecting Samples for Cervical Cancer ScreeningIn guidelines that may encourage more women to get...
- December 10, 2024
.jpg&description=Weight-Loss Meds Like Wegovy Could Battle Alcoholism){kind=link}